In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Gamida Cell (GMDA - Research Report), with a price target of $22.00. The company's shares closed yesterday at $3.23.According to TipRanks, Bernardino is a 5-star analyst with an average return of 26.7% and a 37.67% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Achieve Life Sciences, and Seres Therapeutics.Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $14.80, which is a 358.20% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-gamida-cell-gmda?utm_source=advfn.com&utm_medium=referral
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Gamida Cell Charts.
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Gamida Cell Charts.